Cramer’s Pivot Highlights Shifting GLP-1 Dynamics
Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) experienced sharp volatility following its Q2 2026 earnings release, prompting CNBC’s Jim Cramer to publicly reassess his previously cautious stance. On the August 12 episode of Mad Money, Cramer highlighted a disconnect between the company’s fundamental strength and Wall Street’s initial negative reaction, which saw the stock drop nearly 6% on the day of the report before recovering most losses.
From “Hold” to “Reevaluate”: Tracking Cramer’s Evolution
Cramer’s recent praise marks a significant shift from his earlier commentary. On January 29, 2026, he explicitly favored Eli Lilly (LLY), stating: “I love Eli Lilly and David Ricks… I think that Novo is a hold, not a buy.” By April 27, his tone turned overtly bearish: “Novo Nordisk is going to lose a lot of share on the pill to Eli Lilly. So I say no, we don’t want to be there.” The catalyst for this reversal is the faster-than-expected adoption of oral Wegovy (semaglutide), which has captured a new patient demographic unwilling to use injectables.
Q2 2026 Results: Oral Wegovy Drives Beat-and-Raise
Novo Nordisk reported net sales of DKK 78.49 billion (approx. $12.1 billion), representing 7% growth at constant exchange rates (CER) on an adjusted basis. Adjusted operating profit rose 11% CER to DKK 33.39 billion. The standout performer was the oral Wegovy formulation, launched in January 2026, which has already surpassed 5 million total prescriptions. Crucially, management notes the pill is predominantly reaching treatment-naïve patients, expanding the total addressable market rather than cannibalizing injectable Ozempic/Wegovy sales.
Wall Street Splits on Valuation vs. Execution
Despite the raised guidance, sell-side sentiment remains divided. BMO Capital’s Evan Seigerman maintained a Market Perform rating while lifting his price target to $47 from $45, citing solid pill traction but warning of pricing pressure and an unclear long-term obesity strategy. Berenberg downgraded to Hold with a Copenhagen target cut to DKK 305 from DKK 325, arguing that easy multiple expansion has played out and further upside requires proof of oral market share defense and pipeline breakthroughs.
Institutional Conviction Holds Firm
Hedge fund data tracked through Q1 2026 shows 55 funds maintaining positions in NVO, flat quarter-over-quarter. Fisher Asset Management remains the largest holder despite gradual trimming. Short interest sits at a mere 0.93% of float, signaling minimal speculative bearish positioning. This institutional stability contrasts with retail-driven volatility and suggests sophisticated investors view the oral transition as a positive inflection rather than a threat.
GLP-1 Competitive Landscape Intensifies
The oral GLP-1 race is the critical battleground. Eli Lilly’s orforglipron (Phase 3) and Pfizer’s danuglipron (restarted trials) loom as future oral competitors. However, Novo’s first-mover advantage with an approved, scaling oral product provides a meaningful commercial moat. The company’s ability to manufacture at scale — a historic constraint for peptide orals — will determine whether the 5M prescription milestone translates into sustainable market share.
FAQ
Why did Jim Cramer change his stance on Novo Nordisk?
Cramer reversed his bearish view because the oral Wegovy pill exceeded adoption expectations, reaching 5 million prescriptions in roughly seven months. This traction invalidated his earlier thesis that Eli Lilly would dominate the oral GLP-1 space. The pill is also attracting new patients who refused injections, expanding the overall market rather than just shifting share.
How significant is the Wegovy pill adoption for Novo Nordisk’s revenue?
The oral formulation was the primary driver of Q2 2026 outperformance, helping deliver 7% sales growth and 11% operating profit growth at CER. With 5M+ prescriptions since January 2026 launch, the pill is creating a new revenue stream from previously untreated obesity patients. Management estimates the oral market could eventually surpass injectables in volume due to patient preference.
What are analysts saying about NVO stock after Q2 earnings?
Opinion is split. BMO Capital raised its price target to $47 but kept a Market Perform rating, citing pricing headwinds. Berenberg downgraded to Hold with a DKK 305 target, arguing valuation gains are baked in. The consensus view: execution is strong, but the stock needs pipeline clarity and proof of oral market share sustainability for further multiple expansion.
